Results 121 to 130 of about 59,797 (283)
NEW DOPAMINE AGONISTS IN CARDIOVASCULAR THERAPY
, 1992 Dopamine, a naturally occurring catecholamine, has been extensively used in intensive care for many years. Dopamine stimulates different types of adrenergic receptors: alpha-1 and -2, beta-1 and -2, and dopamine-1 and -2.
SMIT, AJ, GIRBES, ARJ, VANVELDHUISEN, DJ
core +2 more sources
Dopamine agonists and risk of lung cancer in patients with restless legs syndrome. [PDF]
Pharmacoepidemiol Drug Saf, 2023 Hernandez-Con P +3 more
europepmc +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz +2 more
wiley +1 more source
, 2007 Pituitary tumours express both somatostatin and dopamine receptors. Medical treatment with somatostatin analogues is a cornerstone of GH- and TSH-secreting tumours, while treatment with dopamine agonists is a cornerstone of prolactin-secreting tumours ...
COLAO, ANNAMARIA +6 more
core +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Continuous subcutaneous apomorphine infusion (CSAI) is effective in Parkinson's disease but has not been evaluated in multiple system atrophy (MSA). Objective To assess the 6‐month efficacy and tolerability of CSAI in MSA patients. Methods French multicenter retrospective registry‐based analysis of CSAI use in MSA.
Simon Lamy +16 more
wiley +1 more source
A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.
, 2015 Introduction: Dopamine agonists are highly effective as adjunctive therapy to levodopa in advanced Parkinson's disease. These drugs have rapidly gained popularity as a monotherapy in the early stages of Parkinson's disease for patients less than 65-70 ...
CERAVOLO, ROBERTO +3 more
core
Dopamine receptor agonists mediate neuroprotection in malonate-induced striatal lesion in the rat
, 2002 Mitochondrial bioenergetic defects are involved in neurological disorders associated with neuronal damage in the striatum, such as Huntington's disease and cerebral ischemia.
Nappi G. +3 more
core +1 more source
Homogenous Cell Transplantation Trials in Parkinson's Disease: A Systematic Review and Meta‐Analysis
Movement Disorders Clinical Practice, EarlyView.Abstract Background The transplantation of homogenous cells has emerged as an investigational strategy for Parkinson's disease (PD), offering an alternative to symptomatic treatment. Objective We performed a systematic review and meta‐analysis to assess its clinical efficacy and safety.
Nolan Reinisch +4 more
wiley +1 more source
Response of Macroprolactinemia to Dopamine Agonists
Endocrinology Research and Practice, 2008 Macroprolactinemia, defined as hyperprolactinemia with a predominance of the big big prolactin (macroprolactin) isoform, is considered idiopathic and poorly symptomatic. Although macroprolactinemia has been considered to be a cause of apparent resistance
Gonca Tamer +3 more
doaj +2 more sources
Metabolic effects of prolactin and the role of dopamine agonists: A review. [PDF]
Front Endocrinol (Lausanne), 2022 Kirsch P, Kunadia J, Shah S, Agrawal N.
europepmc +1 more source